@Article{biocell.2020.07859,
AUTHOR = {Binbin QIAN, Xiaoduo LIU, Xiaolin GU, Lu YANG, Dake CHEN},
TITLE = {An in vitro study to explore the role of prolylcarboxypeptidase in non-small cell lung cancer},
JOURNAL = {BIOCELL},
VOLUME = {44},
YEAR = {2020},
NUMBER = {1},
PAGES = {19--26},
URL = {http://www.techscience.com/biocell/v44n1/38421},
ISSN = {1667-5746},
ABSTRACT = {Prolylcarboxypeptidase (PRCP) belongs to the S28 family of proteases, which is also a dipeptidyl peptidase.
In this study, we demonstrate the expression pattern of PRCP in Non-small cell lung cancer (NSCLC). We found that
the repression of PRCP expression by small interfering RNA successfully inhibited cell proliferation, migration, and
invasion. Further, we explored the involvement of PRCP in the regulation of epithelial-mesenchymal transition (EMT).
The epithelial marker E-cadherin was significantly increased, meanwhile mesenchymal markers MUC1, vimentin, and
SNAIL were markedly decreased in PRCP knockdown cells. Moreover, the downregulation of PRCP in the NSCLC
cells induced the expression of apoptosis-related proteins in vitro. We performed RT-PCR in 30 pairs of clinical NSCLC
tissues and adjacent non-cancerous tissues, which revealed significantly higher PRCP expression levels in cancer tissues
than in adjacent non-cancerous tissues. Collectively the results from our study suggest a possible cancer promotion role
of PRCP in NSCLC.},
DOI = {10.32604/biocell.2020.07859}
}